Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in
combination with pegylated interferon alpha and ribavirin, are safe and demonstrate
sufficient anti-hepatitis C virus activity.